Zevra Therapeutics (ZVRA) has just been added to several Russell indexes, including multiple value and defensive benchmarks. This inclusion places the stock in front of more institutional screens and passive index trackers.
See our latest analysis for Zevra Therapeutics.
The recent index additions come after a strong run in Zevra Therapeutics' share price, with a 30 day share price return of 20.19% and a 90 day share price return of 46.91%, while the 3 year total shareholder return of 174.55% points to solid longer term momentum despite some near term volatility, including a 1 day share price decline of 3.70%.
If you are looking beyond Zevra Therapeutics for other potential ideas in high growth areas like rare diseases and biotech, this could be a good moment to scan 39 healthcare AI stocks
With Zevra Therapeutics now in multiple Russell indexes and trading at US$13.81, alongside valuation models that imply a large intrinsic discount, the key question is whether investors are still early here or if the market is already pricing in future growth.
Most Popular Narrative: 10.3% Undervalued
According to the most followed narrative on Zevra Therapeutics, a fair value of $15.40 versus the last close at $13.81 points to a modest valuation gap that rests heavily on the rare disease franchise and pipeline outcomes.
The calculated fair value range is approximately $14 to $18, with a midpoint of $15.50. At a current trading price near $13, the stock is fairly valued to slightly undervalued based on existing fundamentals, but it does not represent a deep value opportunity.
Curious what turns Zevra Therapeutics from fairly valued to potentially mispriced in that narrative? The entire framework hangs on concentrated rare disease revenues, rich margins and a handful of high impact clinical readouts that could reshape those cash flow forecasts in either direction.
Result: Fair Value of $15.40 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Zevra Therapeutics still faces key risks, including the reliance on a single rare disease franchise and binary outcomes for late stage trials such as celiprolol.
Find out about the key risks to this Zevra Therapeutics narrative.
Next Steps
With both risks and rewards in play for Zevra Therapeutics, why rely only on headlines when you can review the numbers yourself and move quickly to shape your own view? Start with 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Zevra Therapeutics?
If Zevra Therapeutics has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to uncover fresh stocks that fit your style.
- Spot potential value opportunities early by scanning screener containing 19 high quality undiscovered gems before they appear on more crowded radars.
- Strengthen your defensive core by reviewing solid balance sheet and fundamentals stocks screener (47 results) that pair financial resilience with consistent fundamentals.
- Build a potential income stream by checking 8 dividend fortresses that combine higher yields with a focus on durability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com